Background & Aims Direct-acting antiviral agents (DAAs) are safe and effective in patients
with hepatitis C. Conflicting data were reported on the risk of hepatocellular carcinoma …

Objective We assessed the effectiveness and safety of daclatasvir (DCV) plus sofosbuvir
(SOF), with or without ribavirin (RBV), in a large real-world cohort, including patients with …

Background & Aims We investigated the real-world effectiveness of sofosbuvir,
ledipasvir/sofosbuvir, and paritaprevir/ritonavir/ombitasvir and dasabuvir (PrOD) in treatment …

Viral hepatitis is a major public health threat and a leading cause of death worldwide.
Annual mortality from viral hepatitis is similar to that of other major infectious diseases such …

Summary Direct-acting antiviral (DAA)-induced HCV clearance conceivably leads to
improved outcomes at all stages of liver disease. However, available data suggest that the …

Background & Aims As the long-term benefits of a sustained virological response (SVR) in
HCV-related cirrhosis following direct-acting antiviral (DAA) treatment remain undefined, we …

It is still controversial, whether and to what amount cirrhosis and portal hypertension are
reversible in patients with hepatitis C virus (HCV)‐associated cirrhosis and sustained …

Chronic infection with the hepatitis C virus (HCV) may lead to hepatic fibrosis and eventually
cirrhosis, at which stage, patients have a substantial risk of liver failure, hepatocellular …

Hepatitis C virus infection is a major cause of chronic hepatitis resulting in cirrhosis and
hepatocellular carcinoma (HCC). The recent introduction of direct acting antivirals (DAA) …

Treatment of hepatitis C virus (HCV) infection has experienced a major advancement with
the advent of the new direct acting antivirals (DAA). Current HCV infection cure rates exceed …